{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:08:31Z","timestamp":1760238511363,"version":"build-2065373602"},"reference-count":22,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T00:00:00Z","timestamp":1597363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: The opsoclonus-myoclonus syndrome (OMS) is characterised by opsoclons, myoclons and impaired balance, often concomitant with sleep disorder and behavioural difficulties. The symptoms develop as a result of autoimmune response triggered by a neuroblastic tumour (NT). OMS can also develop secondarily to a viral infection or as an immune response triggered by an unknown agent. This leads to the activation of B- and T-cells, which produce and release autoantibodies or cytokines directly within the central nervous system (CNS), thus damaging the neurons within the cerebellum and the brain stem. The available OMS treatments aim at decreasing lymphocyte, cytokine and autoantibody production or accelerating the utilisation of the latter. Another treatment option for OMS involves using cytostatic agents, which damage T- and B-cells causing their depletion and impaired function, which reduces their ability to produce antibodies and cytokines. Materials and Methods: We present a single-centre experience in treating OMS secondary to NT in 7 children. Results: The combined treatment with cyclophosphamide plus dexamethasone resulted in a complete resolution of OMS symptoms in 4 children, and a significant improvement in the 3 children. Two of them periodically present hyperactivity, and one girl requires an additional support at school due to special educational needs (SEN). Conclusions: NT resection does not resolve OMS in children with OMS secondary to NT. The combined treatment with dexamethasone plus cyclophosphamide seems to be an effective treatment of OMS.<\/jats:p>","DOI":"10.3390\/medicina56080412","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T08:28:35Z","timestamp":1597393715000},"page":"412","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Treatment of Opsoclonus-Myoclonus Syndrome Secondary to Neuroblastic Tumours\u2014Single-Centre Experience and Literature Review"],"prefix":"10.3390","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1984-5527","authenticated-orcid":false,"given":"Agnieszka","family":"Mizia-Malarz","sequence":"first","affiliation":[{"name":"Department of Pediatric Oncology, Haematology and Chemotherapy, Upper Silesia Children\u2019s Care Heatlh Centre, Medical University of Silesia, 16 Medykow Street, 40-752 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weronika","family":"Stolpa","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Haematology and Chemotherapy, Upper Silesia Children\u2019s Care Heatlh Centre, Medical University of Silesia, 16 Medykow Street, 40-752 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gra\u017cyna","family":"Sobol-Milejska","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Haematology and Chemotherapy, Upper Silesia Children\u2019s Care Heatlh Centre, Medical University of Silesia, 16 Medykow Street, 40-752 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,8,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.braindev.2015.11.007","article-title":"Trends and tenets in relapsing and progressive opsoclonus-myoclonus syndrome","volume":"38","author":"Pranzatelli","year":"2016","journal-title":"Brain. Dev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.braindev.2015.09.002","article-title":"Rituximab treatment for relapsed opsoclonus-myoclonus syndrome","volume":"38","author":"Toyoshima","year":"2016","journal-title":"Brain. Dev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1055\/s-0035-1564714","article-title":"Early detection and treatment of neuroblastic tumor with opsoclonus-myoclonus syndrome improve neurological outcome: A review of five cases at a single institution in Japan","volume":"26","author":"Yoneda","year":"2016","journal-title":"Eur. J. Ped. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.braindev.2014.10.010","article-title":"Japanese Society for Pediatric Immune-mediated Brain Diseases. A nationwide survey of opsoclonus-myoclonus syndrome in Japanese children","volume":"37","author":"Hasegawa","year":"2015","journal-title":"Brain. Dev."},{"key":"ref_5","first-page":"219","article-title":"Long-term follow-up of neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome","volume":"40","author":"Parodi","year":"2009","journal-title":"Neuropediatrics"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.pediatrneurol.2015.09.021","article-title":"Opsoclonus-Myoclonus Syndrome, Neuroblastoma, and Insulin-Dependent Diabetes Mellitus in a Child: A Unique Patient","volume":"55","author":"Ghia","year":"2016","journal-title":"Pediatr. Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejpn.2009.03.002","article-title":"A prospective study of the presentation and management of dancing eye syndrome\/opsoclonus-myoclonus syndrome in the United Kingdom","volume":"14","author":"Pang","year":"2010","journal-title":"Eur. J. Pediatr. Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/1043454204272560","article-title":"Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome","volume":"22","author":"Tate","year":"2005","journal-title":"J. Pediatr. Oncol. Nurs."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/mpo.1138","article-title":"Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: Clinical outcome and antineuronal antibodies\u2014A report from the Children\u2019s Cancer Group Study","volume":"36","author":"Rudnick","year":"2001","journal-title":"Med. Pediatr. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejpn.2008.04.012","article-title":"Immunological mechanisms in opsoclonus-myoclonus associated neuroblastoma","volume":"13","author":"Rahaghello","year":"2009","journal-title":"Eur. J. Pediatr. Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1136\/jnnp.25.3.271","article-title":"Myoclonic encephalopathy of infants","volume":"25","author":"Kinsbourne","year":"1962","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00002826-200111000-00007","article-title":"Controlled pilot study of piracetam for pediatric opsoclonus-myoclonus","volume":"24","author":"Pranzatelli","year":"2001","journal-title":"Clin. Neuropharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.braindev.2011.04.005","article-title":"Another promising treatment option for neuroblastoma-associated opsoclonus-myoclonus syndrome by oral high dose dexamethasone pulse: Lymphocyte markers as disease activity","volume":"34","author":"Oguma","year":"2012","journal-title":"Brain. Dev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/pbc.24646","article-title":"Ofatumumab for refractory opsoclonus-myoclonus syndrome following neuroblastoma","volume":"60","author":"Ketterl","year":"2013","journal-title":"Pediatr. Blood. Cancer."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Pranzatelli, M.R., Tate, E.D., McGee, N.R., Travelstead, A.L., Colliver, J.A., Ness, J.M., and Ransohoff, R.M. (2013). BAFF\/APRIL system in pediatric OMS: Relation to severity, neuroinflammation and immunotherapy. J. Neuroinflamm.","DOI":"10.1186\/1742-2094-10-10"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1177\/0883073808324217","article-title":"Insights on chronic-relapsing opsoclonus-myoclonus from a pilot study of mycophenolate mofetil","volume":"24","author":"Pranzatelli","year":"2009","journal-title":"J. Child. Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.pediatrneurol.2005.05.018","article-title":"Delayed, recurrent opsoclonus-myoclonus syndrome responding to plasmapheresis","volume":"33","author":"Armstrong","year":"2005","journal-title":"Pediatr. Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ejpn.2009.12.005","article-title":"Ospoclonus-myoclonus in children associated or not with neuroblastoma","volume":"14","author":"Krug","year":"2010","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/MOP.0b013e32833fde3f","article-title":"Update on diagnosis, treatment, and prognosis in opsoclonus-myoclonus-ataxia syndrome","volume":"22","author":"Gorman","year":"2010","journal-title":"Curr. Opin. Pediatr."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.pediatrneurol.2006.02.008","article-title":"Neuroblastoma found in a 4-year-old after rituximab therapy for opsoclonus-myoclonus","volume":"35","author":"Chang","year":"2006","journal-title":"Pediatr. Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1177\/0883073814549581","article-title":"Effect of increased immunosuppression on developmental outcome of opsoclonus myoclonus syndrome (OMS)","volume":"30","author":"Mitchell","year":"2015","journal-title":"J. Child. Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1542\/peds.2010-3114","article-title":"Outcome and prognostic features in opsoclonus-myoclonus syndrome from infancy to adult life","volume":"128","author":"Brunklaus","year":"2011","journal-title":"Pediatrics"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/56\/8\/412\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:00:37Z","timestamp":1760176837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/56\/8\/412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,14]]},"references-count":22,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["medicina56080412"],"URL":"https:\/\/doi.org\/10.3390\/medicina56080412","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2020,8,14]]}}}